Granted Patent B2

US 12,508,249 · App. 16/858,349 · Granted Dec 30, 2025

Inventor: Roberto A. Maldonado (Berkeley, CA)

Assignee: Cartesian Therapeutics Inc.

A61K31/436A61K9/0019A61K9/127A61K9/5115A61K9/5153A61K9/5192A61K31/192A61K38/19A61K38/21A61K38/37A61K38/43A61K38/47A61K39/39533A61K39/3955A61K45/06A61K47/6923A61K47/6929A61K47/6935A61K47/6937C07K16/18C07K16/241C07K16/40A61K2039/505C12Y305/01001

Abstract

Claims (26)

1 . A method for reducing or preventing an anaphylactic reaction to a non-allergenic antigen, comprising:

providing the non-allergenic antigen, the non-allergenic antigen being unattached to synthetic nanocarriers;

providing a composition comprising synthetic nanocarriers attached to an immunosuppressant; and

administering to a subject having or at risk of having an anaphylactic reaction to a non-allergenic antigen the composition concomitantly with the non-allergenic antigen.

2 . The method of claim 1 , wherein the concomitant administration to the subject is according to a protocol that has been demonstrated to reduce or prevent an anaphylactic reaction.

3 . The method of claim 1 , wherein the method further comprises assessing the anaphylactic reaction in the subject prior to and/or after the administration.

4 . The method of claim 1 , wherein the administering is by intravenous, intraperitoneal or subcutaneous administration.

5 . The method of claim 1 , wherein the method further comprises recording a reduction or prevention of an anaphylactic reaction to the non-allergenic antigen.

6 . The method of claim 1 , wherein the immunosuppressant comprises a statin, an mTOR inhibitor, a TGF-β signaling agent, a corticosteroid, an inhibitor of mitochondrial function, a P38 inhibitor, an NF-κB inhibitor, an adenosine receptor agonist, a prostaglandin E2 agonist, a phosphodiesterase 4 inhibitor, an HDAC inhibitor or a proteasome inhibitor.

7 . The method of claim 1 , wherein the non-allergenic antigen comprises a therapeutic macromolecule.

8 . The method of claim 7 , wherein the therapeutic macromolecule is a therapeutic protein or a therapeutic polynucleotide.

9 . The method of claim 8 , wherein the therapeutic protein is for protein replacement or protein supplementation therapy.

10 . The method of claim 8 , wherein the therapeutic protein comprises a/an infusible or injectable therapeutic protein, enzyme, enzyme cofactor, hormone, blood or blood coagulation factor, cytokine, interferon, growth factor, monoclonal antibody, polyclonal antibody, or protein associated with Pompe's disease.

11 . The method of claim 10 , wherein the infusible or injectable therapeutic protein comprises Tocilizumab, alpha-1 antitrypsin, Hematide, albinterferon alfa-2b, Thucin, tesamorelin, ocrelizumab, belimumab, pegloticase, taliglucerase alfa, agalsidase alfa, or velaglucerase alfa.

12 . The method of claim 10 , wherein the enzyme comprises an ocidforeductase, transferase, hydrolase, lysase, isomerase or ligase.

13 . The method of claim 10 , wherein the enzyme comprises an enzyme for enzyme replacement therapy for a lysosomal storage disorder.

14 . The method of claim 10 , wherein the enzyme comprises imiglucerase, a-galactosidase A (a-gal A), agalsidase beta, acid α-glucosidase (GAA), alglucosidase alfa, arylsulfatase B, laronidase, idursulfase, arylsulfatase B, pegloticase, pegsiticase or galsulfase.

15 . The method of claim 10 , wherein the cytokine comprises a lymphokine, interleukin, chemokine, type 1 cytokine or a type 2 cytokine.

16 . The method of claim 10 , wherein the blood or blood coagulation factor comprises Factor I, Factor II, tissue factor, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor Xa, Factor XII, Factor XIII, von Willebrand factor, prekallikrein, high-molecular weight kininogen, fibronectin, antithrombin III, heparin cofactor II, protein C, protein S, protein Z, protein Z-related protease inhibitor (ZPI), plasminogen, alpha 2-antiplasmin, tissue plasminogen activator (tPA), urokinase, plasminogen activator inhibitor- 1 (PAI 1 ), plasminogen activator inhibitor-2 (PAI2), cancer procoagulant or epoetin alfa.

17 . The method of claim 1 , wherein a load of immunosuppressant attached to the synthetic nanocarriers, on average across the synthetic nanocarriers, is between 0.1% and 50%.

18 . The method of claim 1 , wherein the synthetic nanocarriers comprise lipid nanoparticles, polymeric nanoparticles, metallic nanoparticles, surfactant-based emulsions, dendrimers, buckyballs, nanowires, virus-like particles or peptide or protein particles.

19 . The method of claim 1 , wherein the mean of a particle size distribution obtained using dynamic light scattering of the synthetic nanocarriers is a diameter greater than 100 nm.

20 . The method of claim 1 , wherein an aspect ratio of the synthetic nanocarriers is greater than 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 1:5, 1:7 or 1:10.

21 . The method of claim 1 , wherein the concomitant administration is sequential.

22 . The method of claim 1 , wherein the non-allergenic antigen and composition comprising synthetic nanocarriers attached to an immunosuppressant are administered separately or in different pharmaceutical formulations.

23 . The method of claim 1 , wherein the concomitant administration occurs within one day.

Assignments (2)

Continuity (9)

References Cited (400)